Novavax stock: buy or sell

NVAX stock price: $202.09 0.37% At close on Apr 15th, 2021

Updated on:
Apr 16th, 2021


Novavax stock brief

  • Novavax stock merely changed 0.37% to close at $202.09 on the stock market today, after 3 consecutive sessions in positive.
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

Should I buy Novavax stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is $NVAX stock a buy?

In the current situation of Novavax there is not any eligible buy setup. This doesn't mean we expect a selloff for $NVAX in coming sessions, or that it may not climb higher. Simply, it doesn't match our recommended trading systems

Should I sell Novavax stock?

Knowing when to sell a stock is even harder than knowing when to buy it. Trading strategies help us to avoid impetuous decisions based on our emotions or the noise surrounding the market. Our trading system selects very simple setups to guide us on when is the best moment to sell our shares. Be aware that these setups should not be used for shorting Novavax stock

As a golden rule, you should not mantain an open trade that generates losses greater than those expected by the time of the buy. The moment to sell your stock must always be dictated by the stop-loss (automatic or manual)

Is it time to sell Novavax stock?

In the current situation of Novavax there is not any eligible sell setup, so Novavax stock holders with operations in green can keep their positions

Novavax ratings

In the last month, just one rating was published for Novavax

Novavax analysts' ratings - Last month
Brokerage firmRating
Mar 18th, 2021
HC Wainwright Strong buy

Novavax stock analysis

SMAs overview

NVAX stock SMAs chart

Supports and resistances

The current resistances are:

  • R1: $210.40 (4.11% above)
  • R2: $211.54 (4.68% above)
  • R3: $239.60 (18.56% above)
  • The current supports are:

  • S1: $199.00 (-1.53% below)
  • S2: $196.60 (-2.72% below)
  • S3: $189.40 (-6.28% below)
  • Bollinger bands

    NVAX stock Bollinger Bands chart

    Relative strength index

    The RSI dropped below the overbought level of 70 last February after just crossing to the overbough zone for just one day (weak signal). The RSI value on Thursday was 53.75. Novavax stock sank a 30.26% since RSI lost the overbought zone

    NVAX stock RSI chart

    Novavax stock price history

    Novavax started trading on Dec 5th, 1995 at $67.50 per share1. Since then, NVAX stock surged by 199.39%, with an average of 7.98% per year. If you had invested thousand dollars in Novavax stock at that time, it would be valued $2,993.93 today.

    1: Adjusted price after possible price splits or reverse-splits

    NVAX stock price history chart

    Price target for Novavax stock

    How much a stock will be priced tomorrow or next week is quite unpredictable. Banks and financial organisations publish their analysis forecasting how a particular stock will performance in the future.

    Along with buy or sell recommendations, financial institutions publish their price estimates based on the stock price action and the company fundamental data. Most of these estimates follow the publication of new financial data by the company, and usually. Again, these predictions are not direct recommendations for individual traders and should not be trusted blindly.

    There is just one price target available for Novavax that forecasts a price of $317.00.

    Novavax stock price predictions
    Brokerage firmPrice target
    Mar 18th, 2021
    HC Wainwright $207.00$317.00

    Earnings and financials

    Shareholders event was hosted by Novavax ($NVAX) in early March after posting the earnings report. Novavax reported earnings of $-2.70 per share on revenue of $276.7 million. The consensus earnings estimate was $-1.49 per share on revenue of $304.9 million.

    In contrast, the EPS for the same quarter last year was $-1.13, so posted EPS means a decrease of -138.94%. Revenue skyrocketed a 3,072.18% on an annualized basis in the , from $88.2M to $2.8B last quarter.

    Novavax ($NVAX) posts Q1 financial report mid next May.

    Novavax performance

    NVAX performance compared
    Novavax ($NVAX) -6.00% 59.00% 69.50%

    The comments contained in this article are personal and not recommendations for you to buy or sell stocks. The author of this report does not have any knowledge of the individual conditions of the reader, his or her finances or what is in his or her best interest at any given time. All users should speak with their financial advisor before buying or selling any securities Comments are posted for general educational reasons only

    Novavax summary

    Thursday, April 15th, 2021
    Day range$195.77 - $207.23
    Previous close$201.34
    Session gain0.37%
    Average true range$15.91
    50d mov avg$220.20
    100d mov avg$174.01
    200d mov avg$143.11
    Earnings dateMay 10th, 2021

    Frequently asked questions

    What is Novavax stock symbol?

    Novavax, Inc. is a public company trading in the US stock market with the NVAX symbol

    Is Novavax stock a buy or sell?

    Novavax had one rating in the last 4 weeks Read the article to get additional tips on trading NVAX stock.

    Will NVAX go up?

    Novavax had different price forecasts posted by market analysts in the last month setting the target price to $317.00. That is a 56.86% than the last price ($202.09).

    Latest Novavax news